Finance

Lists
Q3 2026 earnings • released • EPS beat +79.20% • Revenue beat +9.73%
See results
KNSA:NASDAQ
Kiniksa Pharmaceuticals Internatinl, PLC
$95.18
+6.70%
(+5.98) 1D
$95.88
+0.73% (+0.70)
After hours
Closed: Oct 28, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KNSA...
Open
$87.88
High
$95.28
Low
$87.54
Mkt. cap
7.43B
Avg. vol.
691.27K
Volume
1.71M
P/E ratio
96.83
52-wk high
$95.28
52-wk low
$36.56
EPS
$0.98
Beta
0.04
Shares outstanding
48.29M
No. of employees
366
Open
$87.88
High
$95.28
Low
$87.54
Mkt. cap
7.43B
Avg. vol.
691.27K
Volume
1.71M
P/E ratio
96.83
52-wk high
$95.28
52-wk low
$36.56
EPS
$0.98
Beta
0.04
Shares outstanding
48.29M
No. of employees
366
News stories
From web sources and news partners
About Kiniksa Pharmaceuticals Internatinl, PLC
CEO-
Employees366
Founded2015
HeadquartersLondon, England, United Kingdom
SectorBiotechnology
Websitekiniksa.com
Analyst ratings
Based on 5 analysts giving stock ratings to KNSA in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for KNSA in the last 3 months.
Highest
Current $95.18
$107.00 (+12.42%)
Average
$98.60 (+3.59%)
Lowest
$87.00 (-8.59%)
Analyst
Recommendation
Action
Price target
Projected
Date
Paul Choi
Goldman Sachs
Buy
Reiterated
$101.00
+6.1%
10/27/2026
Edward Nash
Canaccord Genuity
Buy
Reiterated
$98.00
+3%
10/23/2026
Geoff Meacham
Citi
Buy
Maintained
$100.00
+5.1%
10/15/2026
Yanan Zhu
Wells Fargo
Buy
Maintained
$87.00
-8.6%
09/29/2026
David Nierengarten
Wedbush
Buy
Reiterated
$99.00
+4%
07/28/2026
Anupam Rama
J.P. Morgan
Buy
Reiterated
$107.00
+12.4%
07/29/2026
Eva Fortea Verdejo
Wells Fargo
Buy
Reiterated
$87.00
-8.6%
07/29/2026
Nicholas Lorusso
TD Cowen
Buy
Reiterated
$95.00
-0.2%
07/28/2026
Roger Song
Jefferies
Buy
Maintained
$71.00
-25.4%
04/28/2026
Unknown Analyst
Wells Fargo
Buy
Maintained
$53.00
-44.3%
04/14/2026
Last report
Oct 27, 2026
Fiscal period
Q3 2026
$0.56 / $0.31
+79.20%beat
Revenue / Est. (USD)
285.97M / 260.61M
+9.73%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
180.86M
202.13M
214.27M
243.60M
Cost of goods sold
83.56M
90.98M
96.37M
111.64M
Cost of revenue
83.56M
90.98M
96.37M
111.64M
Research and development expenses
24.17M
34.61M
27.48M
40.90M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
49.10M
56.78M
61.15M
63.87M
Operating expense
73.27M
91.38M
88.63M
104.76M
Total operating expenses
156.83M
182.36M
185.00M
216.41M
Operating income
24.02M
19.77M
29.27M
27.19M
Other non operating income
3.14M
3.50M
3.41M
3.95M
EBT including unusual items
27.16M
23.27M
32.68M
31.14M
EBT excluding unusual items
27.16M
23.27M
32.68M
31.14M
Income tax expense
8.72M
9.07M
10.09M
5.71M
Effective tax rate
32.12%
38.98%
30.87%
18.34%
Other operating expenses
-
-
-
-
Net income
18.44M
14.20M
22.59M
25.43M
Net profit margin
10.19%
7.02%
10.54%
10.44%
Earnings per share
0.23
0.17
0.27
0.30
Interest and investment income
-
-
-
-
Interest expense
-
-
-
-
Net interest expenses
-
-
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
24.40M
20.24M
29.74M
27.67M
Gain or loss from assets sale
-43.00K
-53.00K
-54.00K
22.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps